vs
Side-by-side financial comparison of Huntington Ingalls Industries (HII) and Viatris (VTRS). Click either name above to swap in a different company.
Viatris is the larger business by last-quarter revenue ($3.7B vs $3.5B, roughly 1.1× Huntington Ingalls Industries). On growth, Huntington Ingalls Industries posted the faster year-over-year revenue change (15.7% vs 5.0%). Viatris produced more free cash flow last quarter ($619.3M vs $516.0M). Over the past eight quarters, Huntington Ingalls Industries's revenue compounded faster (11.3% CAGR vs 0.5%).
Huntington Ingalls Industries, Inc. (HII) is the largest military shipbuilding company in the United States as well as a provider of professional services to partners in government and industry. HII was formed on 31 March 2011, as a divestiture from Northrop Grumman.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
HII vs VTRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.5B | $3.7B |
| Net Profit | $159.0M | — |
| Gross Margin | — | 31.1% |
| Operating Margin | 4.9% | -5.2% |
| Net Margin | 4.6% | — |
| Revenue YoY | 15.7% | 5.0% |
| Net Profit YoY | 29.3% | — |
| EPS (diluted) | $4.06 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.5B | $3.7B | ||
| Q3 25 | $3.2B | $3.7B | ||
| Q2 25 | $3.1B | $3.6B | ||
| Q1 25 | $2.7B | $3.2B | ||
| Q4 24 | $3.0B | $3.5B | ||
| Q3 24 | $2.7B | $3.7B | ||
| Q2 24 | $3.0B | $3.8B | ||
| Q1 24 | $2.8B | $3.7B |
| Q4 25 | $159.0M | — | ||
| Q3 25 | $145.0M | — | ||
| Q2 25 | $152.0M | — | ||
| Q1 25 | $149.0M | — | ||
| Q4 24 | $123.0M | — | ||
| Q3 24 | $101.0M | — | ||
| Q2 24 | $173.0M | — | ||
| Q1 24 | $153.0M | — |
| Q4 25 | — | 31.1% | ||
| Q3 25 | — | 36.6% | ||
| Q2 25 | — | 37.3% | ||
| Q1 25 | — | 35.8% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | — | 38.2% | ||
| Q1 24 | — | 41.2% |
| Q4 25 | 4.9% | -5.2% | ||
| Q3 25 | 5.0% | 4.8% | ||
| Q2 25 | 5.3% | 6.5% | ||
| Q1 25 | 5.9% | -88.9% | ||
| Q4 24 | 3.7% | -5.1% | ||
| Q3 24 | 3.0% | 6.0% | ||
| Q2 24 | 6.3% | -6.3% | ||
| Q1 24 | 5.5% | 5.6% |
| Q4 25 | 4.6% | — | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 4.9% | — | ||
| Q1 25 | 5.4% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.8% | — | ||
| Q1 24 | 5.5% | — |
| Q4 25 | $4.06 | $-0.34 | ||
| Q3 25 | $3.68 | $-0.11 | ||
| Q2 25 | $3.86 | $0.00 | ||
| Q1 25 | $3.79 | $-2.55 | ||
| Q4 24 | $3.15 | $-0.43 | ||
| Q3 24 | $2.56 | $0.08 | ||
| Q2 24 | $4.38 | $-0.27 | ||
| Q1 24 | $3.87 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $1.3B |
| Total DebtLower is stronger | $2.7B | — |
| Stockholders' EquityBook value | $5.1B | $14.7B |
| Total Assets | $12.7B | $37.2B |
| Debt / EquityLower = less leverage | 0.53× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $975.3M | ||
| Q2 25 | — | $566.4M | ||
| Q1 25 | — | $755.0M | ||
| Q4 24 | — | $734.8M | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $917.2M | ||
| Q1 24 | $10.0M | $1.0B |
| Q4 25 | $2.7B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.7B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $5.1B | $14.7B | ||
| Q3 25 | $5.0B | $15.2B | ||
| Q2 25 | $4.9B | $15.6B | ||
| Q1 25 | $4.8B | $15.7B | ||
| Q4 24 | $4.7B | $18.6B | ||
| Q3 24 | $4.2B | $19.8B | ||
| Q2 24 | $4.2B | $19.5B | ||
| Q1 24 | $4.1B | $20.0B |
| Q4 25 | $12.7B | $37.2B | ||
| Q3 25 | $12.3B | $37.9B | ||
| Q2 25 | $12.1B | $38.4B | ||
| Q1 25 | $12.1B | $38.5B | ||
| Q4 24 | $12.1B | $41.5B | ||
| Q3 24 | $11.1B | $44.8B | ||
| Q2 24 | $11.3B | $45.3B | ||
| Q1 24 | $11.2B | $47.3B |
| Q4 25 | 0.53× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.58× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $650.0M | $815.8M |
| Free Cash FlowOCF − Capex | $516.0M | $619.3M |
| FCF MarginFCF / Revenue | 14.8% | 16.8% |
| Capex IntensityCapex / Revenue | 3.9% | 5.3% |
| Cash ConversionOCF / Net Profit | 4.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $794.0M | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $650.0M | $815.8M | ||
| Q3 25 | $118.0M | $744.9M | ||
| Q2 25 | $823.0M | $219.7M | ||
| Q1 25 | $-395.0M | $535.5M | ||
| Q4 24 | $391.0M | $482.7M | ||
| Q3 24 | $213.0M | $826.5M | ||
| Q2 24 | $-9.0M | $379.1M | ||
| Q1 24 | $-202.0M | $614.6M |
| Q4 25 | $516.0M | $619.3M | ||
| Q3 25 | $13.0M | $658.1M | ||
| Q2 25 | $727.0M | $166.8M | ||
| Q1 25 | $-462.0M | $492.9M | ||
| Q4 24 | $277.0M | $342.3M | ||
| Q3 24 | $125.0M | $749.5M | ||
| Q2 24 | $-99.0M | $320.3M | ||
| Q1 24 | $-277.0M | $564.8M |
| Q4 25 | 14.8% | 16.8% | ||
| Q3 25 | 0.4% | 17.6% | ||
| Q2 25 | 23.6% | 4.7% | ||
| Q1 25 | -16.9% | 15.2% | ||
| Q4 24 | 9.2% | 9.7% | ||
| Q3 24 | 4.5% | 20.1% | ||
| Q2 24 | -3.3% | 8.5% | ||
| Q1 24 | -9.9% | 15.5% |
| Q4 25 | 3.9% | 5.3% | ||
| Q3 25 | 3.3% | 2.3% | ||
| Q2 25 | 3.1% | 1.5% | ||
| Q1 25 | 2.5% | 1.3% | ||
| Q4 24 | 3.8% | 4.0% | ||
| Q3 24 | 3.2% | 2.1% | ||
| Q2 24 | 3.0% | 1.6% | ||
| Q1 24 | 2.7% | 1.4% |
| Q4 25 | 4.09× | — | ||
| Q3 25 | 0.81× | — | ||
| Q2 25 | 5.41× | — | ||
| Q1 25 | -2.65× | — | ||
| Q4 24 | 3.18× | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | -0.05× | — | ||
| Q1 24 | -1.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HII
| Aircraftcarriers | $984.0M | 28% |
| Fixedpriceincentive | $758.0M | 22% |
| Submarines | $744.0M | 21% |
| Surfacecombatantsandcoastguardcutters | $452.0M | 13% |
| Amphibiousassaultships | $433.0M | 12% |
| Costtype | $123.0M | 4% |
| Otherprograms | $4.0M | 0% |
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
